Can We Reduce Overtreatment of Cervical High-Grade Squamous Intraepithelial Lesions?

OBJECTIVE: The aim was to evaluate the cytology, colposcopic, and pathological factors associated with the absence of high-grade squamous intraepithelial lesion (HSIL)/cervical intraepithelial neoplasia (CIN) 2-3 lesion on loop electrosurgical excision procedure (LEEP) specimens in women with high-grade cytology and/or HSIL/CIN 2-3 biopsy and the risk of disease persistence/recurrence. MATERIALS AND METHODS: Two-center retrospective study of women undergoing LEEP for high-grade cervical disease between January 2014 and December 2019. Clinical, cytology, colposcopy, and pathology results were evaluated to identify independent predictive factors associated with CIN 1/negative LEEP results. Univariate and multivariate logistic regression models were performed. Follow-up data was evaluated to assess the risk of HSIL/CIN 2-3 persistence/recurrence. RESULTS: Six hundred thirty-nine of 801 women (79.8%) had high-grade cytology and 631 (78.8%) HSIL/CIN 2-3 biopsy. High-risk human papillomavirus test was positive in 98% of women. Loop electrosurgical excision procedure specimen showing CIN 1 or less was found in 27%-31%. Normal/low-grade colposcopy (odds ratio [OR] = 2.17, CI = 1.39-3.39, p = .001) and CIN 1/negative biopsy (OR = 3.25, CI = 2.12-4.99, p < .001) were predictors of negative/CIN 1 LEEP result in women with high-grade cytology. Normal/low-grade cytology (OR = 1.77, CI = 1.19-2.64, p = .005), normal/low-grade colposcopy (OR = 1.66, CI = 1.11-2.49, p = .013), and CIN 2 biopsy (OR = 2.75, CI = 1.73-4.39, p < .001) were predictors in women with HSIL/CIN 2-3 biopsy. Women with a negative/CIN 1 LEEP had lower recurrence/persistence than those with confirmed HSIL/CIN 2-3(1 vs 31, p = .002). Positive endocervical margin (OR = 2.85, CI = 1.10-7.36, p = .03) and high-risk human papillomavirus persistence (OR = 41.3, CI = 16-106.7, p < .01) were predictors of HSIL/CIN 2-3 persistence/recurrence. CONCLUSIONS: A CIN 1/negative LEEP specimen in women with high-grade cytology and/or HSIL/CIN 2-3 biopsy is associated with negative/low-grade cytology, normal/low-grade colposcopic findings and CIN 2 biopsy result before treatment. The HSIL/CIN 2-3 disease persistence/recurrence is low when LEEP specimen does not confirm HSIL/CIN 2-3.

Clinical Challenges in Managing Cervical Intraepithelial Neoplasia 2: A Report From a Cross-sectional Survey.

OBJECTIVES: The aims of the study were to determine the management strategies offered to women with cervical intraepithelial neoplasia 2 (CIN 2) and the attitude of colposcopists toward its histological diagnosis and to identify the criteria used to select women for conservative management. METHODS: Colposcopists working in Spain were invited to participate in an online questionnaire via the Spanish Gynecology and Colposcopy Societies. The survey included 42 questions covering the 3 objectives of the study. One hundred eighty-two colposcopists representing all autonomous regions in Spain responded. The response rate was 26.2%, considering the total number of members. RESULTS: Most colposcopists offer conservative management in selected cases (153/182). The preferred follow-up interval is 6 months (65%), followed by 3-4 months (30%). Observation was considered no longer appropriate after 24 months (29.5%) and 12 months (26.3%), and 24.3% expressed that it depended on women's plan to conceive. During conservative management, 93.9% always perform a cytology, 62.7% human papillomavirus testing, 96.8% colposcopy, 47.9% cervical biopsy, and 28.1% endocervical curettage. Forty-five percent consider that CIN 2 merely represents a misclassified CIN 1 or CIN 3, whereas 46.2% think that CIN 2 lesions are unlikely to regress. Most respondents considered that age older than 40 years (81.3%), human papillomavirus 16 infection (62.1%), HIV infection (76.8%), positive p16 immunostaining (60.2%), a large lesion occupying more than 50% of the cervix (87%), endocervical involvement (91.6%), and previous treatment for CIN 2-3 (77%) are contraindications for conservative management. CONCLUSIONS: Management of CIN 2 remains challenging for colposcopists, and a lack of consensus still exists in clinical practice. A better understanding of the natural history of CIN 2 and its clinical outcomes is still necessary to guide clinicians in its management.

Intraoperative Human Papillomavirus Test Predicts 24-Month High-Grade Squamous Intraepithelial Lesion Recurrence Saving Costs: A Prospective Cohort Study.

OBJECTIVES: The human papilloma virus (HPV) test is recommended in the posttreatment follow-up of cervical intraepithelial neoplasia. The aim of the study was to assess whether the intraoperative HPV (IOP-HPV) test had a similar diagnostic accuracy that HPV test performed at 6 months to predict high-grade squamous intraepithelial lesion (HSIL) recurrence. MATERIALS AND METHODS: In a prospective cohort study, 304 women diagnosed with HSIL by biopsy and/or endocervical curettage before treatment and/or confirmation in the histological specimen were included. Immediately after surgery, HPV testing was performed. This test was compared with the test at 6 months and other predictors of recurrence. Patients were followed for 24 months. An economic analysis was performed to compare the costs of IOP-HPV and HPV test at 6 months. RESULTS: Recurrence rate of HSIL was 6.2% (19 patients). The diagnostic accuracy of the IOP-HPV test to predict HSIL recurrence at 24 months was similar to the HPV test at 6 months, with comparative sensitivities of 100% versus 86.7%, specificities of 82.0% versus 77.9%, positive predictive values of 27.1% versus 18.1%, and negative predictive values of 100% versus 99.0%. Direct economic saving per high-grade intraepithelial lesion patient was 172.8 &OV0556;. CONCLUSIONS: The HPV test performed after loop electrosurgical resection procedure predicted recurrence of HSIL at 24 months with a similar diagnostic accuracy than the HPV test at 6 months. The use of the IOP-HPV test in the management of HSIL will allow early detection of the risk of recurrent disease and to save costs because of potential suppression of the need of HPV and follow-up controls at 6 months.

Prospective Randomized Trial Comparing Transperitoneal Versus Extraperitoneal Laparoscopic Aortic Lymphadenectomy for Surgical Staging of Endometrial and Ovarian Cancer: The STELLA Trial.

BACKGROUND: There is an ongoing debate on which approach, transperitoneal or extraperitoneal, is superior for the performance of laparoscopic aortic lymphadenectomy (LPA-LND) for the surgical staging of gynecologic cancer. A prospective randomized trial (STELLA trial) was designed to compare the perioperative outcomes and node retrieval of extraperitoneal versus transperitoneal aortic lymphadenectomy by laparoscopy or robot-assisted laparoscopy. METHODS: Patients with endometrial or ovarian carcinoma requiring aortic lymphadenectomy for surgical staging were randomized to an extraperitoneal or transperitoneal approach by laparoscopy or robot-assisted laparoscopy between June 2012 and July 2014. RESULTS: A total of 60 patients were entered into the study, 48 with endometrial cancer (80 %) and 12 with ovarian cancer (20 %). Thirty-one patients (51.6 %) were randomly assigned to the extraperitoneal group and 29 to the transperitoneal group (48.3 %). The means LPA-LND operating time was 90 min in both group (p = 0.343). The mean (range) blood loss was 105 (10-400) mL for extraperitoneal versus 100 (5-1000) mL for transperitoneal group (p = 0.541). There were no differences in the number of collected lymph nodes between the two groups [median (range) for extraperitoneal 12 (4-41) vs. 13 (4-29) for transperitoneal (p = 0.719)]. CONCLUSIONS: The extraperitoneal and transperitoneal approaches for laparoscopic and robotic aortic lymphadenectomy provide similar perioperative outcomes and nodal yields. TRIAL REGISTRATION: The STELLA trial is registered at the US National Institutes of Health (ClinicalTrials.gov) #NCT01810874.

Nerve sparing technique in robotic-assisted radical hysterectomy: results.

BACKGROUND: This work assessed the role of robotic-assisted lapararoscopic radical hysterectomy in the treatment of early invasive cervical cancer with special regard to nerve sparing technique. METHODS: Between October 2009 and June 2011, a total of 14 non-consecutive patients underwent early cervical cancer surgery at the authors' institution. Patients with FIGO stage IA2 or IB1 with a tumor size less than or equal to 2 cm underwent radical hysterectomy type B1 and patients with FIGO stage IB1 with a tumor mass bigger than 2 cm underwent a radical hysterectomy using a C1 type technique. RESULTS: Three type B1 and 11 type C1 radical hysterectomies with robotic-assisted laparoscopy were performed using Da Vinci®. The median operation time was 260 min (range 150-300 min). The median follow-up after surgery was 13.7 months (range 1-23 months). During this time, three patients reported anorectal dysfunction while none reported sexual or bladder dysfunction. All patients remain without evidence of disease except one with high risk factors for recurrence. They all are alive. CONCLUSIONS: Laparoscopic robotic-assisted radical hysterectomy with nerve sparing technique is an attractive surgical approach for early invasive cervical cancer. Robotic technology allows a stereoscopic visualization of blood vessels and autonomic nerve supplies (sympathetic and parasympathetic branches) to the bladder and rectum making nerve sparing a safe and feasible procedure.

Situación de las unidades de patología cervical en España. Resultados de una encuesta nacional / Cervical pathology units in Spain today. Results of a national survey

Objetivos. Conocer el grado de implementación de las Unidades de Patología Cervical (UPC) en los hospitales españoles. Describir su organización asistencial y volumen de trabajo, así como sus necesidades formativas, de protocolización y control de calidad, como base para la elaboración de un proyecto conjunto de la Sociedad Española de Ginecología y Obstetricia (SEGO) y la Asociación Española de Patología Cervical y Colposcopia (AEPCC) de Acreditación de UPC. Material y métodos. Análisis descriptivo de los resultados de una encuesta dirigida a los Servicios de Ginecología de los hospitales españoles, entre noviembre del 2012 y enero del 2013. De las 220 encuestas enviadas, se obtuvo respuesta en 128 (58%), representando a todas las comunidades autónomas españolas. Resultados. El 70% de los hospitales encuestados disponen de UPC. La media de ginecólogos que trabajan a tiempo completo en la UPC es de 3 y a tiempo parcial, de 20. El promedio de actividad anual reportada fue de 178 nuevos diagnósticos, 79 casos de neoplasia intraepitelial de cérvix 2 positivas y 87 cirugías de conización cervical. El 60% de los hospitales disponen de registros de complicaciones y de correlaciones citológicas, colposcópicas e histológicas. Un 90% sigue las recomendaciones de AEPCC y SEGO para la prevención primaria y secundaria del cáncer de cérvix. Más del 90% de los médicos consultados considerarían adecuado que la AEPCC y la SEGO promoviesen la acreditación de las UPC. Conclusiones. La situación global de las UPC en España es buena pero mejorable en algunos aspectos. La mayoría de los centros ven adecuada la existencia de una acreditación para las UPC (AU)

Objectives. To determine the extent to which Cervical Pathology Units (CPU) are implemented in Spanish hospitals and to describe their organization and workload and requirements for training, standardization, and quality assurance, as a basis for a joint project of the Spanish Society of Obstetrics and Gynecology (SEGO) and the Spanish Association of Cervical Pathology and Colposcopy (AEPCC) for CPU accreditation. Material and methods. We performed a descriptive analysis of the results of a survey of Gynecology Services at Spanish hospitals between November 2012 and January 2013. A total of 220 surveys were sent and replies were received from 128 services (58%) representing all the Spanish regions. Results. A total of 70% of the hospitals in the survey had a CPU. There was an average of 3 full-time gynecologists and 20 part-time gynecologists at each CPU. The mean annual reported activity was 178 new cases, 79 cervical intraepithelial lesions 2 positive, and 87 conizations. Sixty percent of the hospitals had a register of complications and cytological, colposcopic and histological correlations. Ninety percent followed the recommendations of the AEPCC and the SEGO for primary and secondary prevention of cervical cancer. More than 90% of the gynecologists believed it would be appropriate for the AEPCC and the SEGO to promote CPU accreditation. Conclusions. The overall situation of CPU in Spain is good but could be improved. Most hospitals in the survey believe that implementing the accreditation process would not be difficult (AU)

Encuesta sobre el uso en España de la prueba para la determinación del virus del papiloma humano / Survey on the use of tests for the detection of human papilloma virus in Spain

Objetivo. Conocer el conocimiento de las recomendaciones españolas para el cribado del cáncer de cuello uterino (CCU) y evaluar la utilización por los ginecólogos en España de las pruebas de detección del virus del papiloma humano (VPH). Sujetos y métodos. Encuesta dirigida a ginecólogos de la Sociedad Española de Ginecología y Obstetricia y la Asociación Española de Patología Cervical y Colposcopia. Se recogieron los datos aportados por 141 especialistas. Resultados. Participó el 30% de la población objeto de estudio. El 95,6% conocía las recomendaciones. El 93,5% utilizaba habitualmente la técnica de detección del VPH (el 77,7% como cribado de CCU). Los criterios de uso variaron considerablemente entre participantes. El principal motivo para no usar la técnica fue su falta de disponibilidad. Conclusiones. Es necesario reforzar la formación e información sobre las recomendaciones disponibles acerca de las nuevas estrategias de cribado y, en particular, del uso clínico de la determinación del VPH (AU)

Objective. To determine knowledge of the Spanish guidelines for cervical cancer screening, and to evaluate the use of tests for the detection of human papilloma virus (HPV) by Spanish gynecologists. Subjects and methods. The survey focused on gynecologists who were members of the Spanish Society of Gynecology and Obstetrics and the Spanish Association of Cervical Pathology and Colposcopy. One hundred forty-one specialists completed the questionnaire. Results. Thirty percent of the target population participated. A total of 95.6% were aware of the recommendations and 93.5% routinely used the test for the detection of the HPV (77.7% for cervical cancer screening). The criteria for the use of the test varied considerably among participants. The main reason for not using the technique was its unavailability. Conclusions. Training and information on the available recommendations for the new screening strategies and, particularly, on the clinical use of HPV determination should be reinforced (AU)